Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03104114 · ClinicalTrials.gov registry record · NA
Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication
A NA study, sponsored by Boston Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 216
- Enrollment target
NCT03104114 is a NA study that has completed, run by Boston Medical Center. The registered enrollment target is 216 participants.
The verdict
NCT03104114, a NA study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 216 participants
- Enrollment target
Study Summary
Boston Medical Center provides care to cancer patients on oral cancer medications through the use of Boston Medical Center Specialty Pharmacy (BMC SP). The use of oral medications in cancer treatments is relatively new and unfortunately, very little is known about adherence in cancer patients. This study will evaluate the influence of a pharmacist-driven medication management program on adherence and persistence rates. Boston Medical Center's Specialty Pharmacy Adherence Program (B-SPAP), will utilize a high-touch counseling model involving clinical pharmacist that will focus on educating patients about their oral cancer treatments. The program will require face-to-face counseling with a pharmacist, through the use of a proven patient teaching tool, prior to initiating treatment with oral oncolytic treatments and, periodically thereafter, based on protocol. This study will help improve our understanding of the role of the pharmacist in cancer patients. In addition, the study will help identify independent factors that may contribute or impact adherence. The outcomes of this program will be compared to a historical control group of patients that have already received treatment for their cancer through the BMC Specialty Pharmacy.
Interventions
- BEHAVIORAL pharmacist-intervention
- BEHAVIORAL Historical control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2017-05-02 |
| Est. Completion | 2019-02-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03104114
The ClinicalTrials.gov registry entry for NCT03104114 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacist-intervention is the first listed.
NCT03104114 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03104114 about?
NCT03104114 is a clinical study titled "Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication". Boston Medical Center provides care to cancer patients on oral cancer medications through the use of Boston Medical Center Specialty Pharmacy (BMC SP). The use of oral medications in cancer treatments is relatively new and unfortunately, very little is known about adherence in cancer patients. This ...
What is the current status of trial NCT03104114?
This trial is currently completed. It is a NA study. The enrollment target is 216 participants. The study started on 2017-05-02. Estimated completion is 2019-02-15.
What interventions are being tested in trial NCT03104114?
The interventions under investigation include: pharmacist-intervention (BEHAVIORAL), Historical control (BEHAVIORAL).
Who is sponsoring clinical trial NCT03104114?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.